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ABSTRACT
Membrane-associated lipoproteins have important functions in bacterial pathogenesis and
physiology. According to the available genomic sequences, C. jejuni possesses multiple
lipoproteins, but the majority of them have not yet been functionally characterized. To better
understand the pathogenic mechanisms of C. jejuni, in this work we characterized a three-
gene operon (cj0089, cj0090, and cj0091) encoding a cluster of lipoproteins. It was shown
that this lipoprotein-encoding operon is indirectly regulated by CmeR, a transcriptional
regulator repressing the expression of the multidrug efflux pump CmeABC in C. jejuni. We
determined that Cj0091 is an outer membrane associated protein, identified it as a new
adhesin in C. jejuni, and demonstrated that this protein is involved in Campylobacter
colonization in vivo. This study suggests that Cj0091 may be a promising candidate for the
development of vaccines to reduce Campylobacter colonization in animal hosts.
1CHAPTER 1. GENERAL INTRODUCTION
Introduction
Campylobacter jejuni is a leading cause of acute gastroenteric diseases worldwide. In the
United States, it is estimated that 2.4 million cases of human Campylobacter infections occur
annually (24). Although Campylobacter enteritis is generally a self-limiting disease in
developed countries, it causes significant childhood morbidity and mortality in developing
countries. Campylobacter infection can also develop to Guillain-Barré syndrome (GBS), an
autoimmune-mediated neurodegenerative complication (71). Campylobacter is also among
the most common bacterial causes of diarrhea among travelers returning from developing
countries (75). Most of the human Campylobacter infections are caused by consumption of
under-cooked chickens (32). In contrast to Salmonella where control in poultry is quite
successful, effective intervention strategies remain to be developed for control of
Campylobacter infections.
Despite the high incidence of infections caused by Campylobacter, virulence factors and
mechanisms involved in pathogenesis are still poorly known. A few putative virulence
factors have been discovered so far. For example, PEB1 and CadF were identified as
adhesion molecules (51, 80). Both are involved in adhesion and invasion of human intestinal
epithelial cells. In addition, PEB1 may also be involved in utilization of aspartate and
glutamate by binding to these amino acids, which are important sources of carbon and energy
in Campylobacter (27). The multidrug efflux pump CmeABC contributes significantly to
2Campylobacter colonization in the intestinal tract by mediating bile resistance (59).
Flagellum, which is one of the best studied virulence factors in Campylobacter, is involved in
motility, chemotaxis, invasion, and in vivo colonization. Campylobacter seems to produce a
variety of toxic activities, but cytolethal distending toxin (CDT) is the only toxin identified in
Campylobacter so far (24). Lipooligosaccharide (LOS) is involved in the interaction with
host cells and functions as an endotoxin, which induces host intestinal inflammatory
responses (39, 67, 100). In addition, LOS mimics human gangliosides, which is considered a
key factor in the development of GBS (6, 54). Recently, two lipoproteins, JlpA and CapA,
have been characterized and they appear to be involved in adhesion of Campylobacter to host
epithelial cells (5, 42).
Bacterial lipoproteins have diverse functions in physiology and pathogenesis (8, 44).
Based on the genomic sequence of C. jejuni NCTC 11168, it is predicted that C. jejuni
possess twenty two lipoproteins (8). So far, only two of them, JlpA and CapA, have been
functionally characterized (5, 42, 43). A previous work conducted by our laboratory revealed
that several lipoprotein-encoding genes including cj0089 and cj0091 were down-regulated in
the cmeR mutant background, suggesting that CmeR, a transcriptional repressor for the
multidrug efflux pump CmeABC, is a potential activator for the lipoprotein genes. cj0089
and cj0091 along with cj0090 are tandemly positioned on the Campylobacter chromosome
and likely form an operon. However, the role of this cluster of lipoproteins in Campylobacter
pathophysiology is unknown. In this project, we characterized the regulation of the
lipoprotein operon and examined the function of Cj0089 and Cj0091 in Campylobacter
adherence and colonization using both in vitro and in vivo experiments. It was found that
3Cj0091 functions as an adhesin and contributes to the early-stage colonization of
Campylobacter in the intestinal tract of chickens. These findings improve our understanding
of Campylobacter pathogenesis and suggest the possibility that lipoproteins can be used as
vaccine candidates for the control of Campylobacter colonization.
Thesis organization
This thesis consists of three chapters. The first chapter is a literature review including
general overview of Campylobacter and Campylobacter infections; characteristics of
bacterial outer membrane proteins and lipoproteins; and mechanisms and virulence factors
involved in the adhesion and invasion of C. jejuni. The second chapter describes the study
characterizing the three-gene operon encoding the lipoprotein cluster. The third chapter is the
general conclusion.
4Literature review
Microbiology and genomics
C. jejuni is a gram-negative bacterium with a curved or spiral shape. The organism
possesses a single, polar, unsheathed flagellum at one or both ends, which allows a
characteristics corkscrew-like motion. C. jejuni grows best at 37 ºC to 42 ºC, which are the
body temperatures of animals and birds. The optimal growth of the organism requires a
microaerophilic atmosphere consisting of 5 % O2, 10 % CO2, and 85 % N2 (98).
Currently the complete genome sequences of three C. jejuni strains are available
including NCTC 11168, RM1221, and 81-176. C. jejuni has a circular chromosome with the
size of about 1.6 to 1.8 megabases. Approximately 1,600 proteins are encoded in
NCTC11168 and 811-76, and 1,800 in RM1221. The G + C contents of all three
chromosomes are low, at approximately 30 %. The average length of ORFs is about 900 bp.
The genome of C. jejuni is quite dense and over 90 % of the genome codes for proteins (79).
Several unique features were found from the genomic sequences of these three strains of C.
jejuni. The first one is the general lack of insertion sequence (IS) elements, except for a copy
of putative IS605 (31, 79). The second important feature is the presence of hypervariable
sequences on the chromosomes. Variations in the length of poly G:C tracts, which is due to
DNA polymerase slippage during DNA replication, form several hypervariable regions of the
genomes. These variable regions are localized in the genes involved in biosynthesis of
lipooligosaccharide (LOS) and capsular polysaccharide (CAP), flagellar modification, and
5DNA restriction-modification (RM) (78). C. jejuni is speculated to have no intact DNA
repair systems since many of the genes important for direct repair, mismatch repair, and SOS
response are missing in the genome. Lack of a DNA repair system may contribute to the
rapid phase and sequence variations in this organism. In Campylobacter, the frequent
variations in components of surface structures may play an important role in the adaptation to
the host intestinal environments rather than in avoiding host immune responses (79).
The major difference between C. jejuni RM1221 and the other two sequenced strains is
the presence of four prophages/genomic islands in the genome of RM1221 (31). CJIE1 is a
Mu-like phage and is located upstream of argC (CJE0275). CJIE1 has genes encoding Mu-
like phage protein (68), although their functions are unknown. CJIE2 and CJIE4 are found in
the 3’ end of arginyl- and methionyl-tRNA genes, respectively. These elements include genes
predicted to encode phage-related endonucleases, methylases, or repressors. Since no major
phage structural proteins (capsid, portal and scaffold protease proteins) are found in CJIE2, it
is predicted that CJIE2 may be an intact prophage with novel head structures, a satellite
phage, nonfunctional prophage, or genomic island. (31). On the other hand, CJIE4 is similar
to a putative prophage found in the genome of C. lari RM2100, the integrated elements 1
(CLIE1). In CJIE4, a few genes encoding phage structural proteins were identified (31).
CJIE3 is integrated into the 3’ end of an arginyl-tRNA, and is predicted to be a genomic
island or integrated plasmid rather than a prophage since no phage-related genes are found
(31).
6The genome of C. jejuni 81-176 is syntenic with the genome of C. jejuni NCTC 11168
and RM1221 but is disrupted by some duplications, deletion, or insertion of genes. Some of
the genes involved in capsule biosynthesis and posttranslational modification of flagellar
proteins are missing from C. jejuni 81-176 (38). In contrast, C. jejuni 81-176 possess
additional genes, which are absent or represented as pseudogenes in C. jejuni NCTC 11168
and RM1221. These include genes involved in electron transport, energy metabolism,
anaerobic respiratory system, and integrated plasmids (38).
The unique feature of C. jejuni 81-176 is that it carries two large plasmids, pTet and pVir.
The pTet plasmid carries the tetO gene, making C. jejuni 81-176 tetracycline resistant. The
pVir plasmid contains genes encoding orthologs of type IV secretion proteins found in
Helicobacter pylori (10). Type IV secretion system is usually involved in conjugation and
translocation of DNA and proteins (21). It seems that the pVir plasmid is involved in
invasion as well as natural transformation in Campylobacter (9).
Clinical manifestation
Clinical manifestations of Campylobacter infections differ between developing and
industrialized countries. In developing countries the infection is often asymptomatic or mild,
and non-inflammatory, inducing watery diarrhea (24) and mostly affecting children of less
than 2 years of age (22). In industrialized countries, the infection of Campylobacter can be
very severe. The most prominent features include abdominal pain, diarrhea, and fever (3, 75,
92). The degree of diarrhea varies from loose, watery to bloody. The stools may contain fecal
7leukocytes and red blood cells (3), and patients may suffer fever, accompanied by headache,
dizziness, and myalgia (3). The divergence in the clinical features of Campylobacter
infections may be due to differences in serotypes and virulence factors, or host immune
responses (24, 75).
The mean incubation period of Campylobacter enteritis is 3.2 days with a range of 18 h
to 8 days (92). The acute diarrhea usually lasts for 2-3 days and abdominal pain persists for
another few days (47, 92). Persistence or relapse of illness may occur occasionally (45).
Campylobacter can be isolated from patients’ feces for several weeks even after the illness
has resolved (47, 92). Campylobacter enteritis is usually self-limiting and the development of
complications is rare. The most significant complication following Campylobacter infection
is GBS (Guillain-Barré syndrome). Although it was estimated that 30-40 percent of GBS
patients had recent infections with C. jejuni, the risk of actually developing GBS after
Campylobacter infections is quite low, approximately 1 GBS case out of 1,000
Campylobacter infections (2, 71). GBS is the most frequent cause of acute neuromascular
paralysis (71, 85). The symptoms include weakness of the limbs and the respiratory muscles,
areflexia (loss of reflexes), and raised protein concentrations in cerebrospinal fluid (70, 71).
GBS is a clinically diverse disorder, which includes both acute inflammatory demyelinating
polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) (82). Certain
Campylobacter serotypes are more frequently associated with GBS. In the United States and
Japan, Penner serotype O:19 is the most frequently associated strain with GBS (70, 82),
while in South Africa O:41 strains seems to be more associated with disease (82). GBS
usually occurs 1 – 3 weeks after the infection (70), which indicates that humoral
8immunopathogenic mechanisms are involved (3). Several studies have shown that certain O
serotypes of C. jejuni have an LOS core structure homologous to a number of different
glycosphingolipids of the gangliosides on the surface of host cells (7, 70, 71, 82, 104, 105).
This molecular mimicry seems to be an important cause of GBS.
Epidemiology
C. jejuni resides in the intestinal tracts of many wild and domestic animals as a
commensal organism. The organism is especially found in domestic poultry, such as
chickens, turkeys, ducks, ostriches, and wild birds including cranes, geese (63), and seagulls
(36).
The major route of C. jejuni infection for poultry is via horizontal transmission from
environmental sources. Some studies have suggested vertical transmission of C. jejuni via
eggs may occur, but evidence proving this hypothesis has not been conclusively documented
(13, 89). Potential factors associated with horizontal transmission include wild birds, rodents,
other livestock on or nearby the farms, pets, and insects.
Campylobacter is often found in the intestine of wild birds. It is highly possible that
contamination of poultry farm environments by wild-bird feces contributes to the spread of
this organism (89). Indeed, Barrios et al. showed a strong association of vertical ventilation
systems in poultry houses with Campylobacter infection in poultry. They speculate that the
9vertical fans create an environment to attract wild birds by producing heat, which may lead to
the falling of their feces to the houses through the fans (13).
The other sources of infection for poultry include clothing and footwear of farmers,
transport crates, and vehicles. Some studies have shown the reduced number of
Campylobacter infection in poultry by applying hygiene measures including disinfection or
changing of boots before entering the poultry houses, and cleaning and disinfection of the
houses before repopulation and transport crates (41, 95-97). Therefore, farm workers or
visitors and farm equipment may also be involved in the spread of Campylobacter between
poultry and farms (89).
During processing, broiler carcasses are contaminated by fecal materials due to rupture of
intestines (23, 87). Because multiple flocks are processed at a given time, poultry flocks that
are negative for Campylobacter can be contaminated with Campylobacter from
Campylobacter-positive flocks, leading to high prevalence of Campylobacter on chicken
carcasses.
In humans, the majority of Campylobacter infections occur as sporadic cases rather than
outbreaks. The most significant source of sporadic Campylobacter infections is the
consumption of undercooked chickens or mishandling of the birds during food preparation in
the kitchen (32). Contact with poultry, other farm animals, pet, and wild birds can contract
the infection as well. In addition, consumption of contaminated water and raw, unpasteurized
milk has been associated with both sporadic and outbreak cases of Campylobacter infection
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(32). Cross-contamination of other foods by raw chicken meats (in kitchens and other
processing sites) is also a risk factor for Campylobacteriosis.
Treatment
Most cases of Campylobacter infection do not require antibiotic treatment unless patients
suffer a persistent high fever, bloody diarrhea, or prolonged diarrhea. Antibiotic treatment is
often required for patients who are pregnant, HIV infected, or immunocompromised.
Erythromycin or fluoroquinolone are used to treat Campylobacter infections. Campylobacter
has developed high-level resistance to fluoroquinolone antibiotics, but the resistance rate to
erythromycin is still low (72). Since erythromycin is of low cost and has low toxicity, is acid-
resistant, and remains unabsorbed in the gut, it is now considered the first-choice drug for
treating Campylobacter infections (3, 18).
Fluoroquinolones are often used to treat patients with the symptoms of bacterial
gastroenteritis. When the causative agents responsible for the enteric disease are unknown,
fluoroquinolones are considered the first choice because many enteric pathogens are
susceptible to this class of antibiotic, but intrinsically resistant to macrolide antibiotics
(including erythromycin). Since the symptom of gastroenteritis caused by Campylobacter
and other organisms, such as Salmonella and Shigella, are undistinguishable,
fluoroquinolones can be prescribed for patients in the lack of a diagnosis (3).
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However, there is a rapid increase in fluoroquinolones-resistant strains of Campylobacter
worldwide (3). Fluoroquinolones, including sarafloxacin and enrofloxacin, were used in
drinking water to treat bacterial respiratory infections in poultry (93). The increased
resistance to fluoroquinolones in human isolates of Campylobacter seems to be correlated
with the approval of fluoroquinolones for use in food animals (3, 93). In various countries,
isolation of fluoroquinolone-resistant Campylobacter from retail chicken products has been
documented (93). In addition, studies using PCR-based restriction length polymorphism
(PCR-FLA) revealed that strains of fluoroquinolone-resistant C. jejuni isolated from both
human and from chicken products were shown to be the same (93). Use of fluoroquinolones
in veterinary medicine is considered a major cause of the increase in infections with
fluoroquinolone-resistant strains.
Prevention
An ideal way to control Campylobacter infection in humans would be to reduce the
prevalence of Campylobacter in poultry flocks and the level of cross-contamination during
carcass processing (3, 4). According to several studies, application of appropriate hygiene
measures seems to reduce the contamination of Campylobacter in poultry flocks on farms
(41, 95-97). These hygiene procedures include proper cleaning and disinfection of poultry
houses, equipment, and transport crates, control of insects and rodents entering in the houses,
and disinfection or changing of footwear and clothes at the entrance of each poultry houses.
However, even the strict measures only delay the onset of Campylobacter colonization, or
maintain the reduction of Campylobacter contamination level only in a short time (74). The
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multi-source feature of flock contamination by Campylobacter makes it difficult to control
Campylobacter using hygiene measures.
During processing in slaughterhouses, air chilling and water chilling along with use of
chlorinated water reduce Campylobacter concentration on the poultry carcasses (87, 94). In
addition, freezing of poultry carcasses reduced the contamination level (87), likelydue to the
fact that Campylobacter is sensitive to the freeze-thaw process.
Irradiation is highly effective in reducing pathogens in food. In poultry and red meat the
safe use of irradiation technology was approved and confirmed by Food and Drug
Administration (FDA) (84). Low-dose irradiation can reduce the number of Campylobacter
as well as other food-borne pathogens such as Salmonella and E. coli O157:H7 significantly
(20, 30). However, despite the effectiveness and safe use of irradiation technology, few meat
and poultry industry are applying this technology in the U.S. (23).
Vaccination against Campylobacter in broiler chickens would be an ideal strategy to
prevent chickens from colonization by Campylobacter. However, an effective vaccine has
not yet been available. The great antigenic diversity of Campylobacter between different
strains and poor knowledge of antigens conferring protective immunity make the
development of vaccines challenging. Most of the reported immunization studies were not
able to show a significant level of protection against Campylobacter in chicken (48, 74, 86).
On the other hand, a study by Wyszyska et al. (101) showed promising results. In their
protection experiment, they immunized chickens orally with an avirulent Salmonella vaccine
13
strain expressing the C. jejuni cjaA gene, which encodes a protein that is highly
immunogenic in chickens and well conserved among different Campylobacter serotypes.
After the challenge with the wild-type C. jejuni, a reduction in bacterial colonization in the
ceca of immunized chickens were observed. In contrast, all of the non-vaccinated control
chickens were heavily colonized with C. jejuni. This study suggests that vaccination is a
promising approach to control Campylobacter infection in chickens (101).
Limited efforts have been made in the development of vaccines against Campylobacter
infection in humans. The enteric diseases program at the Naval Medical Research Institute,
Bethesda, MD reported a vaccine candidate consisting of killed whole Campylobacter cells
(CWC) (11, 12). The CWC vaccine showed a high efficacy of protection against C. jejuni in
non-human primates and mice. In addition, it was demonstrated that the combined use of
CWC and the heat-labile enterotoxin of E. coli (LT) increased the immune response
compared with CWC alone (11, 12). A truncated recombinant flagellin subunit vaccine,
which was tested in mice by the nasal route with LT, also showed a high protection against
C. jejuni (56). In addition, Antex (USA) is developing an oral Traveler’s Diarrhea vaccine
(activax) expressing antigens from Campylobacter, Shigella, and enterotoxigenic E. coli
(ETEC) (35). Despite these efforts, an effective Campylobacter vaccine for human use is still
not available.
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CmeR and CmeR regulation
CmeR was originally identified as a repressor for the multidrug efflux pump CmeABC in
C. jejuni (57). The CmeR gene, which encodes a 210-residue protein, is located immediately
upstream of the cmeABC operon (57). The intergenic region (IT) between cmeR and cmeABC
is 97-bp and contains an inverted repeat (IR) operator site (57). Lin et al. (57) showed that
CmeR directly binds to the IR, inhibiting the expression of cmeABC. When cmeR or the IR
was mutated, a drastic increase in the level of cmeABC expression was observed, indicating
that CmeR acts as a local repressor for cmeABC.
CmeABC functions as a multidrug efflux pump (or MDR pump) and is encoded by a
three-gene operon. This operon encodes three proteins including the outer membrane protein
(CmeC), an inner membrane drug transporter (CmeB), and a periplasmic membrane-fusion
protein (CmeA) (57). CmeABC plays a role in the extrusion of various substrates such as
antibiotics, as well as ions, and lipophilic compounds such as SDS and bile salts. This
indicates that CmeABC contributes to the intrinsic resistance of C. jejuni to a broad range of
antimicrobials (19, 57, 64, 83, 103). Interestingly CmeABC is also required for the
adaptation of C. jejuni in the gastrointestinal tract of chickens by mediating resistance to bile
salts. These compounds are present in animal intestinal tracts and have bactericidal activities
(61).
CmeR has sequence and structural homologies to the members of the TetR family of
transcriptional repressors (57). In the N-terminus of CmeR in particular, there is a DNA-
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binding domain, which is well conserved within the TetR family, such as QacR of
Staphylococcus aureus, AcrR of Escherichia coli, and MtrR of Neisseria gonorrhoeae (57).
In TetR, three-helix bundles form the DNA-binding domain and two of the helices form a
helix-turn-helix motif, which can also be found in the N-terminal domain of CmeR (57, 77).
While the N-terminal regions of TetR family members are conserved, their C-terminal
regions vary, which enables them to interact with diverse substrates. A study by Lin et al.
(59) showed that expression of the cmeABC was greatly induced in the presence of various
bile salts. It also showed that bile salts inhibited CmeR binding to the promoter region of
cmeABC. These findings indicate that bile salts function as inducing ligands for CmeR (59).
It has been hypothesized that conformational changes in the N-terminal DNA-binding region
of CmeR occur upon binding of inducing ligands to the C-terminal domain, which results in
the release of CmeR from its operator DNA allowing the transcription of cmeABC (59).
Recently our laboratory also showed that CmeR functions as a pleiotropic regulator in C.
jejuni. By comparing the transcriptional levels in 11168 and its CmeR mutant using DNA
microarrays, multiple genes affected by the CmeR mutation were identified. The majority of
the CmeR-regulated genes identified by microarray were confirmed by quantitative real-time
RT-PCR. These identified genes encode diverse functions involved in membrane transport,
capsular polysaccharides biosynthesis, C4-dicarboxylate transport/utilization, and
metabolism. Several periplasmic proteins and lipoproteins of unknown functions are also
regulated by CmeR. For example, cj0089 and cj0091, which encode putative lipoproteins, are
down-regulated in the CmeR mutant, suggesting that CmeR acts as an activator for the genes.
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Membrane proteins of Campylobacter
The cell envelope of gram-negative bacteria consists of an inner membrane (IM) and an
outer membrane (OM). While the IM is composed of phospholipids showing a symmetrical
structure of the inner and outer leaflet, the OM is asymmetric in that it contains
lipopolysaccharides (or lipooligosaccharides) on the outer leaflet. Besides the
lipopolysaccharides/lipooligosaccharides and phospholipids, the OM of gram-negative
bacteria consists of outer membrane proteins (OMPs), which account for about half of the
OM mass (49). OMPs include integral membrane proteins and lipoproteins. Integral OMPs
usually have a -barrel structure, in which hydrophilic residues face outward. These OMPs
play essential roles in maintaining the integrity and permeability of bacterial membranes (17,
60), as well as adaptation in host niches such as iron uptake and resistance to antimicrobial
peptides, sera, antibiotics, and bile salts (60).
Only a limited number of membrane proteins in C. jejuni have been functionally
characterized. CadF (Campylobacter adhesion to fibronectin) and PEB1 (51, 81) are involved
in Campylobacter adhesion and/or invasion to epithelial cells. CadF, a 37-kDa OMP,
mediates the binding of the organism to fibronectin located at cell-to-cell contact regions in
the gastrointestinal epithelium and stimulates the host cell signal transduction pathway (51,
66). PEB1 is a periplasmic protein homologous to the periplasmic-binding protein
component of amino acid ABC transporters (80). PEB1 is an adhesin involved in
Campylobacter adherence and invasion to human cells and colonization in the intestinal guts
of mice (81). It was also shown that PEB1 binds to aspartate and glutamate (27). C. jejuni is
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not able to utilize glucose as a carbon source, nor is it capable of sugar catabolism (99).
Therefore, amino acids (especially serine, proline, aspartate, asparagines, glutamine, and
glutamate) appear to be the important sources of carbon and energy (46, 55, 99). Thus, the
PEB1 transport system appears to have an important role in utilization of aspartate and
glutamate. However, how PEB1, a periplasmic protein, functions as an adhesin in C. jejuni is
unknown. The major outer membrane protein (MOMP) functions as a porin (26) and also
appear to be involved in Campylobacter adherence to human intestinal cell membranes and
fibronectin (69, 99). MOMP is an integral protein (15, 106) and has a molecular mass of 45
kDa (62). As a porin, MOMP has pore-forming activity, which allows the diffusion of a wide
range of compounds to bacterial cells (26). The other well-characterized membrane proteins
are the multidrug efflux pumps, CmeABC and CmeDEF, both of which belong to the
resistance-nodulation-cell division (RND) efflux systems (58, 61). The regulation and
function of CmeABC has been described in the previous section. CmeDEF is also encoded
by a three-gene operon and composed of an outer membrane channel protein CmeD, a
periplasmic fusion protein CmeE, and an inner membrane transporter CmeF (58). In contrast
to CmeABC, this efflux pump is not regulated by CmeR. Nonetheless, CmeDEF is also
involved in resistance to several antibiotics and toxic compounds. Compared to CmeABC,
CmeDEF is expressed at a low level and contributes moderately to antibiotic resistance in C.
jejuni (1). It appears that CmeABC and CmeDEF interact with each other in conferring
antimicrobial resistance and maintaining cell viability (1).
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Bacterial lipoproteins
Bacterial lipoproteins are structurally and functionally diverse proteins. A common
feature shared by all bacterial lipoproteins is that they contain N-acyldiacylglyceryl-cysteine
(Cys) at their N-terminal ends (37). This is the result of posttranslational modification, which
is a significant characteristic of all the lipoproteins. This modification is very important since
the three fatty acyl groups at the N-terminal end enable even highly hydrophilic proteins to
anchor to the hydrophobic membranes (8). The precursor of a lipoprotein is a prolipoprotein,
which contains a signal sequence of a tripartite structure: n-region, h-region, and c-region.
The n-region is positively charged due to the presence of lysine and/or arginine, the h-region
is hydrophobic, and the c-region contains lipobox, which is a consensus sequence around the
signal cleavage site, comprised of (LVI)(ASTVI)(GAS)-C (8, 44, 73).
The biosynthesis of bacterial lipoproteins involves three steps as described by Sankaran
and Wu (90). First, the diacylglyceride of phosphatidylglycerol is transferred to the thiol of
Cys in a prolipoprotein by prolipoprotein-phosphatidylglycerol diacylglycerol transferase.
Then, the signal peptide of the modified prolipoprotein is cleaved off by signal peptidase II,
which is the leading formation of apolipoprotein. Lastly, amino-acylation of the N-terminal
Cys of apolipoprotein takes place by phospholipid-apolipoprotein transacylase to form a
mature lipoprotein (90). This biosynthetic pathway of bacterial lipoproteins occurs on the
periplasmic side of the inner membrane after the precursors have been synthesized in the
cytosol (73). Lipoproteins are anchored either on the inner or outer membranes facing toward
the periplasmic place. They can also be located on the surface of outer membranes. To be
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able to function correctly, they need to be localized properly on cell membranes. Since the
lipid region of lipoproteins is very hydrophobic, protein export machinery, such as the Lol
system in E. coli is required in order to transfer lipoproteins through the hydrophilic
periplasmic space (73). Although the amino acid positions +2 and +3 of lipoproteins were
previously thought to be the determinants for their localization to either inner or outer
membranes (34, 102), it seems that this is not always the case (91).
Lipoproteins have diverse functions as adhesins, antigens, enzymes, transporters, binding
proteins, and toxins. In C. jejuni NCTC 11168, the number of predicted lipoproteins is
twenty two (8). So far, there are only two lipoproteins in C. jejuni that have been
characterized. Jin et al. (42) characterized a surface-exposed lipoprotein, JlpA, which has a
molecular mass of 42.3 kDa. This lipoprotein is loosely associated with the surface of the
bacterial cell and appears to mediate Campylobacter adherence to host epithelial cells (42).
Further study indicates that JlpA interacts specifically with surface-exposed heat shock
protein 90 (Hsp90) on host cells and triggers signaling pathways leading to the activation
of NF-B and p38 MAP kinase, both of which are components involved in host
proinflammatory responses to infections (43). Recently, another lipoprotein, CapA, was
characterized in C. jejuni (5). CapA also mediates Campylobacter adherence to host
epithelial cells and is involved in the colonization of chicken gut.
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Adhesion and invasion of Campylobacter jejuni
C. jejuni is able to reside in the mucous layer as a free-living organism and can also
invade into host cells (100). Motility is essential for the organism to be able to colonize host
intestinal cells. A drastic reduction in motility and intestinal colonization was observed with
the flaA mutant. flaA is the primary structural gene of flagellum in Campylobacter (29). The
motility provided by flagella enables the organism to penetrate the mucous layer (100). Once
the organism reaches the apical surface of the epithelium, it adheres to the host cells via
adhesion molecules. So far, the putative adhesins of C. jejuni include MOMP (69),
lipooligosaccharide (33, 65), PEB1 (80), CadF (51),, JlpA (42), and CapA (5).
Cellular invasion is an important pathogenic mechanism of C. jejuni. The invasion of
epithelial cells in vivo results in cellular damage and function loss, which lead to stimulation
of host inflammatory responses and diarrhea (100). Standard assays for studying adhesion
and invasion are available. Cell lines such as INT 407, Caco-2, and HEp-2 are commonly
used in these assays. The ability of C. jejuni to invade host cells seems to vary depending on
the strain (28, 47, 50). Clinical strains are more invasive than laboratory strains (50). C.
jejuni strain 81-176 is highly invasive, and studies on the invasion mechanism of C. jejuni
are mostly based on this strain.
Many invasive bacterial pathogens seem to enter into the host cells via cytoskeletal
rearrangement. The cytoskeleton of eukaryotic cells is composed of various filaments
including actin filaments, microtubules (MT), and accessory proteins (53). The invasion
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mechanisms of C. jejuni vary, but mostly require either actin filaments or MTs (25, 40, 50,
76), or both(14, 76), or neither (88). C. jejuni 81-176 invades host cell in a MT-dependent
manner (16, 24, 40). It also seems that microtubule motors are involved in the uptake and
intracellular motility of this strain (16, 24).
Hu and Kopecko (40) conducted kinetic studies of entry of C. jejuni 81-176 into INT 407
cells. According to their study, the invasion of C. jejuni is most efficient at the lowest starting
multiplicities of infection (MOI) of 0.02, but the number of internalized C. jejuni reaches its
highest at an MOI of 200, where the efficiency of invasion is lower. This indicates that C.
jejuni is a “highly efficient solitary invader” when compared to Salmonella typhi invasion,
which seems to require enough signaling of bacteria to host cells in order for the
internalization to occur (40). Using direct visualization, which allowed direct observation of
bacteria in infected INT 407 cells, the authors also found that about two bacteria are
internalized per infected host cell regardless of MOI (40). The internalization of C. jejuni is
thus strictly limited (40). This might be due to host factors, such as a limited number of host
cell “invasion receptors” and entry sites and host cell modifications to prevent further entry
of C. jejuni, or due to the fact that the entry of the organism is dependent on host cell cycles
(39, 40). The initiation of invasion requires the host cytoskeletal rearrangement triggered by
signals from C. jejuni. CiaB (52) appears to be an effector of host cell signaling, but its exact
role in invasion is still unknown.
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CHAPTER 2. Cj0091, an immunogenic lipoprotein of Campylobacter jejuni, is required
for the adherence to host epithelial cells and colonization of the intestinal tract of
chickens.
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Abstract
Bacterial lipoproteins have important functions in bacterial pathogenesis and physiology.
In Campylobacter jejuni, a major foodborne pathogen causing gastroenteritis in humans, the
majority of lipoproteins have not been functionally characterized. In this work, we identified
a three-gene operon (cj0089, cj0090, and cj0091) encoding a cluster of lipoproteins. It was
shown that this lipoproteins-encoding operon is regulated by CmeR, a transcriptional
regulator repressing the expression of the multidrug efflux pump CmeABC in C. jejuni. In
contrast to the regulation of CmeABC, CmeR appears to activate the expression of the
lipoprotein genes and the regulation is possibly via an indirect mechanism. Analysis of
different cellular fractions indicated that Cj0089 was associated with the inner membrane,
while Cj0091 was located on the outer membrane. Inactivation of cj0091, but not cj0089,
significantly reduced the adherence of C. jejuni to INT 407 cells in vitro, indicating that
Cj0091 function as an adhesin. When inoculated into chickens, the Cj0091 mutant also
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showed a defect in early colonization of the intestinal tract, suggesting that Cj0091
contributes to Campylobacter colonization in vivo. It was also shown in this study that
Cj0091 was produced and immunogenic in chickens that were naturally infected by C. jejuni.
These results identify Cj0091 as a new adhesin in C. jejuni and suggest that it may be
targeted to reduce Campylobacter colonization in animal hosts.
Introduction
Campylobacter jejuni is a Gram-negative, curved or spirally shaped bacterium with a
single, polar, unsheathed flagellum at one or both ends (62). It is a commensal organism
existing in the intestinal tracts of a variety of wild and domestic animals, especially in birds.
Campylobacter jejuni is a leading cause of acute diarrhea in humans worldwide (22). The
typical symptoms of Campylobacter infections in humans include watery to bloody diarrhea,
abdominal pain, fever, and presence of leukocytes and red blood cells in feces (3, 60).
Campylobacter infections can also develop to Guillain-Barré syndrome (GBS), an
autoimmune-mediated neurodegenerative disorder which causes acute neuromascular
paralysis (44, 53). The most significant source of Campylobacter infections for humans is the
consumption of undercooked chicken.
The pathogenic process of C. jejuni in humans has not been well understood, but can be
divided into several stages (25). Once ingested by the host, C. jejuni survives the stresses in
the stomach and small intestine. Upon reaching to the large intestinal tract, C. jejuni
colonizes mucus layer and adheres to the intestinal cell surface of the host gastrointestinal
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tract. The organism produces a cytolethal distending toxin and possibly other toxins, but their
role in pathogenesis is not clear (51). Once adhered to the host intestinal epithelial cells, C.
jejuni may invade into and proliferate within the host cells. The invasion and proliferation of
the organism inside host cells are considered the cause of cell damage and induce host
inflammatory responses, which result in diarrhea with fecal leukocytes (25). Occasionally C.
jejuni can spread to extraintestinal sites, such as liver, gallbladder, pancreas, uterus, and fetal
tissues (25, 60).
The known putative virulence factors involved in Campylobacter pathogenesis include
flagella, lipooligosaccharide (LOS), cytolethal distending toxin (CDT), and outer membrane
proteins (25, 64). Flagella aid Campylobacter to move through the mucus layer and
contribute to colonization and invasion (25). LOS is involved in adherence to host cells and
serves as an endotoxin that induces host intestinal inflammatory responses (25, 42, 64). In
addition, molecular mimicry of LOS to human gangliosides is considered a key factor in the
development of GBS (6, 33). CDT causes cell cycle arrest and host DNA damage, which
induce host inflammatory responses (20, 34, 65). The outer membrane proteins of
Campylobacter are involved in interactions with hosts and play important roles in adherence
and colonization. CadF, a 37-kDa surface protein, binds to fibronectins located at cell-to-cell
contact regions in the gastrointestinal epithelium. CadF is required for Campylobacter
colonization of chickens (32, 71). PEB1 is a periplasmic protein homologous to a solute-
binding component of amino acid ABC transporters (48). PEB1 is important for C. jejuni
adherence to human cells and colonization in the intestinal tract of mice (49). The major
outer membrane protein (MOMP), a 45-kDa porin, adheres in vitro to human intestinal cell
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membranes and fibronectin (43), but whether it is involved in in vivo adherence is unknown.
CmeABC functions as an efflux pump to extrude a variety of substrates such as antibiotics,
ions, SDS, and bile salts (12, 37, 38, 52, 68). In addition, CmeABC mediates bile resistance
and is required for C. jejuni colonization in the gastrointestinal tract of chickens (37).
Bacterial lipoproteins have diverse functions including cell adhesion, transport, nutrient
acquisition, stimulation of inflammatory/immune responses in host cells, mating, and serum
resistance (8). C. jejuni has multiple membrane lipoproteins predicted from the genomic
sequences (8). At present, only two of these lipoproteins, JlpA (29) and CapA (5), have been
functionally characterized in C. jejuni. JlpA, which is a surface-exposed, loosely cell-
associated lipoprotein, is involved in the interaction of C. jejuni with the surface-exposed
heat shock protein 90 (Hsp90) of host cells and triggers signal transduction, leading to the
activation of components (NF-B and p38 MAP kinase) involved in host proinflammatory
responses to infections (30). CapA is also involved in Campylobacter adherence to host
epithelial cells and colonization in gastrointestinal tract of chicken (5).
In a previous study, we found that several putative lipoproteins in C. jejuni were
regulated by CmeR (Table 1). CmeR was previously identified as a transcriptional repressor
for the multidrug efflux pump CmeABC (36). Using DNA microarray, we also found that
CmeR functions as a pleiotropic regulator modulating the expression of multiple genes in C.
jejuni NCTC 11168. In total, 28 genes showed  2-fold changes in expression in the CmeR-
deletion mutant compared with the wild-type strain. Among the CmeR-regulated targets
include two genes (cj0089 and cj0091) encoding putative lipoproteins (Table 1). cj0089 and
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cj0091, along with cj0090 (also encoding a putative lipoprotein) appear to be organized into
an operon, but their detailed regulatory mechanisms and role in Campylobacter
pathophysiology remain unknown. Considering the fact that bacterial lipoproteins have
important functions and the majority of lipoproteins in C. jejuni have not been characterized,
we conducted both in vitro and in vivo experiments to elucidate the regulation of the
lipoproteins-encoding operon and the functions of their encoded products in Campylobacter
adherence and colonization.
Materials and methods
Bacterial strains, plasmids, and culture conditions. The various bacterial strains,
mutants, and plasmids used in this study are listed in Table 2. Campylobacter strains were
routinely grown in Mueller-Hinton (MH) broth (Difco) or agar at 42 °C with an atmosphere
of 5 % O2, 10 % CO2, and 85 % N2. Escherichia coli strains were grown is Luria-Bertani
(LB) broth (Difco) or agar at 37 °C with shaking at 250 rpm. Media were supplemented with
ampicillin (Amp) (100 µg/ml), kanamycin (Km) (50 µg/ml), or chrolamphenicol (Cm) (4
µg/ml for Campylobacter, 20 µg/ml for E. coli) as needed.
PCR. All primers used for PCR are listed in Table 3. PCR amplification was performed
in a volume of 100 µl containing 200 µM of each deoxynucleoside triphosphate, 200 nM
primers, 2.5 mM MgSO4, 100 ng of template DNA and 5 U of Taq DNA polymerase
(Promega) or pfu Turbo DNA polymerase (Stratagene). Cycling conditions varied depending
on the estimated annealing temperatures of the primers and the expected size of the products.
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PCR products were purified with a QIAquick PCR purification kit (QIAGEN). For reverse
transcriptase PCR (RT-PCR), total RNA was isolated from C. jejuni NCTC 11168 using the
RNeasy minikit (QIAGEN). Isolated total RNAs were treated with RNase-free DNase
(QIAGEN) to remove contaminating genomic DNA, and this was followed by quantification
and qualification of the RNA using a NanoDrop microscale spectrophotometer (NanoDrop
Technologies). RT-PCR was conducted using the SuperScript™ III One-Step RT-PCR
system with Platinum® Taq DNA Polymerase (Invitrogen). Cycling conditions for the RT-
PCR were as follows: synthesis of cDNA at 50 ˚C for 30 min; denaturation at 94 ˚C for 2
min, followed by 40 cycles of 94 ˚C for 15 s, 55 ˚C for 30 s and 72 ˚C for 2 min 30 s; and a
final extension at 72 ˚C for 10 min. The negative control was a RT-PCR mixture with the
Taq polymerase (Promega) without the RT step, while the positive control was a reaction
with genomic DNA as the template.
Deletional mutation of cj0089. An isogenic cj0089 mutant was constructed by
deletional mutagenesis in C. jejuni strain NCTC 11168. To construct the cj0089 mutant,
primers cj0089-F5 and cj0089-R5 (Table 3) were used to amplify the 1915-bp fragment
containing the entire open reading frame (ORF) of cj0089 and its flanking sequences from C.
jejuni strain NCTC 11168 chromosomal DNA. The PCR product was digested with SphI and
SacI and cloned into pUC19 to form pUC19-89. Inverse PCR was performed using pfu Turbo
DNA polymerase (Stratagene) on pUC19-89 using primers cj89-U2 and cj89-L2 (Table 3),
which resulted in a 460-bp deletion within cj0089. A kanamycin-resistance (KanR) cassette,
amplified from pMW10 by pfu Turbo DNA polymerase (Stratagene), was inserted to the
amplified product to obtain pUC19-89K. The suicide vector, pUC19-89K, was introduced
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into C. jejuni strain NCTC 11168 by electroporation. Transformants were selected on MH
agar containing Km (50 µg/ml). Disruption of cj0089 by deletion of the partial ORF and
insertion of the KanR gene with the right orientation was confirmed by PCR, and the cj0089
mutant was named Cj89-.
Insertional mutation of cj0091. An isogenic cj0091 mutant was constructed by
insertional mutagenesis in C. jejuni strain NCTC 11168. The 1724-bp fragment containing
the entire open reading frame (ORF) of cj0091 and its flanking sequences was amplified
using primers cj0091-F2 and cj0091-R2 (Table 3) from C. jejuni strain NCTC 11168
chromosomal DNA. The PCR product was digested with SacI and XbaI and cloned into
pUC19, forming pUC19-91. pUC19-91 was digested with ClaI followed by Klenow
treatment (Takara) to form blunt ends. The KanR cassette, amplified from pMW10 by pfu
Turbo DNA polymerase (Stratagene), was inserted to the ClaI-digested and Klenow-treated
pUC19-91 to obtain pUC19-91K. The suicide vector, pUC19-91K, was introduced into C.
jejuni strain NCTC 11168 by electroporation. Transformants were selected on MH agar
containing 50 µg of Km per ml. PCR was performed to confirm the disruption of cj0091 by
the KanR gene with the right orientation, and the cj0091 mutant was named Cj91-.
Expression and purification of recombinant Cj0089 and Cj0091. Histidine (His)-
tagged recombinant Cj0089 and Cj0091 (rCj0089 and rCj0091, respectively) were produced
in E. coli using the pQE-30 vector of the QIAexpress System (QIAGEN). A 1323-bp
sequence covering cj0089 was amplified using primers cj0089F and cj0089R (Table 3). A
567-bp fragment of cj0091 was also amplified using primers cj0091-F1 and cj0091-R1
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(Table 3). The amplified products containing restriction sites at the 5’-ends (Table 3) were
purified and digested with appropriate restriction enzymes and separately ligated into pQE-
30 vectors. The predicted lipoprotein signal peptides of Cj0089 and Cj0091 were not
included in the recombinant products. Thus, the recombinant products represented the mature
proteins in C. jejuni. Cloning, expression and purification of rCj0089 and rCj0091 were
performed using the procedures provided by the QIAexpress system. The purified proteins
were washed with 1 x PBS (containing 10mM benzamidine) to remove imidazole and were
concentrated using Ultracel®YM-30 (for Cj0089) and Ultracel®YM-10 (for Cj0091)
(Millipore).
Production of rabbit antisera. A polyclonal rabbit antiserum against rCj0089 was
generated in our laboratory. A New Zealand white rabbit was immunized three times with
rCj0089 at a 2-week interval between the injections. Each immunization used 100 µg of
rCj0089 emulsified in incomplete Freund’s adjuvant. The animal was sacrificed at week 6
post the first injection to collect the antisera against rCj0089. Polyclonal antiserum against
rCj0091 was generated in two rabbits by Pacific Immunology Corp (San Diego, CA, USA).
The antisera were stored at -80 °C for further use.
Electrophoretic mobility shift assays. To determine whether CmeR directly binds to the
operator region of cj0089, electrophoretic mobility shift assays, as described by Alekshun et
al. (2), were performed with slight modifications. The 179-bp promoter region of cj0089 was
amplified using primers Pcj89-F1 and Pcj89-R1 (Table 3). The amplified product was then
labeled at the 3’ end with digoxigenin-11-ddUTP (DIG-11-ddUTP) using the DIG
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Oligonucleotide 3’-End Labeling kit (Roche Molecular Biomedicals). The DIG-11-ddUTP-
labeled DNA (0.2 pmol) was incubated with different amounts of recombinant CmeR (0, 75,
and 150 ng) in 20µl binding buffer containing 20 mM HEPES (pH 7.6), 1 mM EDTA, 10
mM(NH4)2SO4, 5 mM dithopthreitol, 0.2 % Tween-20, 30 mM KCl, and 25 ng of poly(dI-
dC). The reaction mixtures were incubated at room temperature for 30 min, followed by
electrophoresis on a nondenaturing 6 % (w/v) polyacrylamide gel in a 0.25 x TBE buffer (22
mM Tris, 22 mM boric acid, 0.5 mM EDTA, pH 8.0) at 200 V for 40 min. The DNA was
transferred from the gel to a positively charged nylon membrane using a vacuum blotter.
Alkaline phosphatase-conjugated anti-DIG antibody and the chemiluminescent substrate
CDP-star (Roche Molecular Biochemicals) were sequentially applied to the membrane. The
chemiluminescence signals on the blots were captured using a digital imaging system
(chemiLmager™5500 from Alpha Innotech). The promoter DNA of cmeABC and the
intragenic fragment of cmeA were used as the positive and negative controls, respectively, as
described in a previous study (36).
Preparation of cell fractions. The cell fractions of cytoplasm, periplasm, inner
membrane, and outer membrane were obtained using the method described by Leon-Kempid
et al. (17), with a slight modification. In total, 500 ml of an overnight culture of C. jejuni
strain NCTC 11168 were harvested by centrifugation at 5000 x g for 30 min, and the cell
pellet was resuspended in 20 ml of the ST buffer (20 % w/v sucrose, 30 mM Tris-HCl, pH
8.0) at room temperature. EDTA was added to the cell suspension to a final concentration of
1 mM and the suspension was incubated for 10 min at room temperature with shaking. The
cells were then centrifuged at 8000 x g for 10 min at room temperature to collect the cell
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pellet. The supernatant was discarded. The pellet was resuspended and stirred in ice-cold 10
mM Tris-HCl (pH 7.5) at 4 ˚C for 10 min followed by centrifugation at 15,000 x g at 4 ˚C for
15 min. The supernatant was concentrated by 10 % TCA and kept as the periplasmic fraction.
The pellet was again resuspended in 5 ml of ice-cold 10 mM Tris-HCl (pH 7.5), followed by
sonication (Virsonic, an SP Industries Company) by three bursts of 30 s at the 6 µm
amplitude and centrifugation at 13,000 x g at 4 ˚C for 15 min. The pellet was discarded. The
supernatant was ultracentrifuged at 100,000 x g at 4 ˚C for 1 hour. The supernatant was then
transferred to a new tube and again centrifuged at 100,000 x g at 4˚C for 1 hour. The
supernatant was concentrated by 10 % TCA, corresponding to the cytoplasmic fraction. The
pellet collected was the total membrane fraction. The isolation of inner and outer membrane
was performed using the method of Carlone et al (14). The pellet of membrane fraction was
washed three times with ice-cold 10 mM Tris-HCl (pH 7.5) and resuspended in 0.2 ml of 10
mM HEPES buffer (pH 7.4). An equal volume of sarkosol buffer (2 % sodium N-
lauroylsarkosine, SIGMA) was added and incubated at room temperature for 60 min, during
which the solution was mixed occasionally. The inner membrane proteins were solubilized at
this step. The mixture was centrifuged at 15,600 x g for 30 min at 4 ˚C. The supernatant was
kept as the soluble inner membrane fraction. The pellet was washed with 0.5 ml of 10 mM
HEPES buffer followed by resuspension in 200 µl of 10 mM HEPES buffer. This fraction
was the outer membrane fraction. The fractions were analyzed by SDS-PAGE and
immunoblotting.
Adhesion assays. Adhesion assays were performed according to the method described by
Jin et. al. (29), with some modifications. INT 407 cells (ATCC CCL-6) were grown in
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Minimum Essential Medium (MEM) (GIBCO) containing 10 % fetal bovine serum (FBS),
100 µg/ml streptomycin, and 100 units/ml penicillin G (GIBCO) at 37 ˚C under the
atmosphere of 5 % CO2. Once the INT 407 cells become confluent, the monolayers were
trypsinized and approximately 1 x 105 cells/well in MEM with 10 % FBS without antibiotics
were applied to each well of a 24-well tissue culture plate, which was incubated at 37 ˚C for
18 h under the atmosphere of 5 % CO2. The monolayers were washed twice with 1 x PBS.
NCTC 11168, cj89-, and cj91- that grew overnight were added to wells containing
monolayers in 1 ml of MEM with 10 % FBS at an INT 407 cells-to-bacteria ratio of 1:100,
and incubated at 37 ˚C under the atmosphere of 5 % CO2 for 3 h. The monolayers were
washed five times with 1 x PBS. The washed monolayers were then lysed with 0.2 ml of 1 %
(w/v) Triton X-100 in PBS for 15 min. The Campylobacter cells were enumerated by plate
counting on MH agar plates. All assays were repeated three times and were done in
quadruplicate.
Colonization in chicken. To examine whether the mutations of cj0089 and cj0091 affect
C. jejuni colonization in chicken, 3-day-old commercial broiler chickens (ross x cobb),
purchased from a commercial hatchery, were inoculated via oral gavage with approximately
107 CFU of NCTC 11168, Cj89-, or Cj91- (each group consists of 15 birds). Cecal samples
were collected from 5 birds from each group at 3, 6, and 10 days post the inoculation (DPI),
homogenized, serially diluted in 1 x PBS, and plated on MH plates containing
Campylobacter-specific selective agents and growth supplements (SR084E and SR117E;
Oxoid). After two-day incubation at 42 ˚C under microaerophilic conditions, the
Campylobacter colonies were counted.
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Results
Genomic organization and cotranscription of cj0089, cj0090, and cj0091. The three
genes encoding the cluster of lipoproteins are tandemly positioned on the chromosome of C.
jejuni NCTC 11168 (Fig. 1). cj0089 and cj0090 are separated by 9 nucleotides, while cj0090
and cj0091 are separated by 23 nucleotides. No predicted stem-loop structures exist between
the ORFs. According to the prediction by Petersen et al. (50), there is a putative RpoD
promoter located upstream of cj0089. The TATA-box of this promoter is located 40
nucleotides upstream of the cj0089 translational initiation codon. No promoter was predicted
immediately upstream of cj0090 or cj0091 (50). To determine whether cj0089, cj0090, and
cj0091 are co-transcribed, RT-PCR was performed using primers cj89int-F and cj91int-R
(Table 3), which span the three ORFs (Fig.1A). A 1194-bp expected product was amplified
in the PCR reaction with the RNA and RT, while no product was obtained in the reaction
without RT, suggesting that cj0089, cj0090, and cj0091 are con-transcribed and likely
organized into an operon (Fig 1B). The operon is flanked by an upstream gene encoding an
anaerobic C4-dicarboxylate transporter (dcuA) and a downstream gene encoding a
hypothetical protein. There is a potential Rho-independent transcriptional terminator forming
a 23-nucleotide stem-loop structure located immediately downstream of dcuA (Fig. 1A).
Another stem-loop structure is present downstream of cj0091 (Fig.1A). These sequence
features further support the notion that the three lipoprotein genes form an operon.
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Predicted features of the lipoproteins. Analysis of amino acid sequences predicted
from DNA sequence analysis indicated that cj0089, cj0090, and cj0091 encode putative
lipoproteins because each of them has a typical N-terminal lipoprotein signal peptide. LipoP
algorithm (31) predicted a signal peptidase II cleavage site at LFLTAC for Cj0089, at
FLLSAC for Cj0090, and at LLFSGC for Cj0091. Cj0089 (453 amino acids), Cj0090 (122
amino acids), and Cj0091 (207 amino acids) each encodes a protein with a calculated
molecular mass of 51.28 kDa, 13.92 kDa, and 22.32 kDa, respectively. The molecular masses
of the mature lipoproteins, after cleavage of the signal peptides, are predicted to be 49.4 kDa,
12.29 kDa, and 20.51 kDa, respectively. BLAST searches showed that cj0089 bears
similarity to tetratricopeptide TPR-2 repeat proteins found in Shewanella spp. The functions
of these tetratricopeptide TPR-2 repeat proteins have not been characterized. Cj0089 also has
a 27.4 % similarity to HP0018, a hypothetical protein in Helicobacter pylori. Cj0091 has a
33.5 % similarity to HP1457 and has a conserved domain similar to the collagen-binding
surface adhesin, SpaP (antigen I/II family) of Yersinia pestis biovar Orientalis, where its
function has not been determined empirically.
Production of rCj0089 and rCj0091 and their specific antibodies. The coding
sequences of cj0089 and cj0091, excluding their signal peptides, were cloned into pQE-30
vector, expressed in E. coli JM109, and the proteins purified by affinity chromatography.
Using the purified proteins, rabbit polyclonal antibodies against rCj0089 and rCj0091 were
produced. The anti-Cj0089 antibody recognized a protein with a molecular mass of 49 kDa in
NCTC 11168. On the other hand, anti-Cj0091 recognized a protein with a molecular mass of
approximately 18 kDa in the organism, slightly smaller than the calculated mass of Cj0091
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(20.51 kDa). These immunoblotting results indicated that both lipoproteins were produced in
C. jejuni when grown in MH broth.
Regulation of cj0089 and cj0091 by CmeR. In a previous DNA microarray study by our
laboratory, it was found that cj0089 and cj0091 were down-regulated in the cmeR mutant,
suggesting that CmeR is an activator for the lipoprotein genes (Table 1). To confirm the
previous finding at the protein level, the expression levels of Cj0089 and Cj0091 in the wild-
type strain and in the cmeR mutant were analyzed by immunoblotting using anti-Cj0089 and
anti-Cj0091. MOMP was used to normalize the loading condition. The immuoblotting results
clearly showed that the production of Cj0089 and Cj0091 in the cmeR mutant was decreased
compared with that in the wild-type (Fig. 2). According to the measurements with the
AlphaEase® software (Alpha Innotech), the band intensity of Cj0089 was 2.98 fold higher in
the wild-type than in the CmeR mutant and the band intensity of Cj0091 was 1.92 fold higher
in the wild-type than in the CmeR mutant. The immunoblotting data further confirmed the
results of the DNA microarray and real-time RT-PCR.
To determine if CmeR directly or indirectly regulates the lipoprotein operon, a gel
mobility shift assay was performed using rCmeR and the promoter sequence in front of
cj0089. The promoter DNA was amplified with primers Pcj89-F1 and Pcj89-R1 (Table 3,
Fig. 3A). rCmeR did not bind to the promoter region of cj0089 when different concentrations
of rCmeR were used in the assay (Fig. 3B). As a positive control, rCmeR bound to the
promoter DNA of cmeABC, and as a negative control, rCmeR did not bind to the internal
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region of cmeA. These findings suggest that the lipoprotein operon is indirectly regulated by
CmeR.
Cj0089 and Cj0091 are membrane-associated proteins. In order to determine the
cellular localization of Cj0089 and Cj0091, C. jejuni strain NCTC 11168 was fractionated to
isolate proteins from the cytosol, periplasm, inner membrane, and outer membrane. The
fractions were examined by immunoblotting with anti-Cj0089 and anti-Cj0091 (Fig. 4).
Cj0089 was detected predominantly in the inner membrane fraction, while Cj0091 was found
in both the inner and outer membrane fractions, but the majority of Cj0091 was in the outer
membrane. Antisera against CmeB, an inner membrane drug transporter of multidrug efflux
pump CmeABC (37), and against the major outer membrane protein (MOMP) (27), were
used as controls for the membrane fractions. CmeB is exclusively detected in the inner
membrane fraction; however, MOMP was detected in both outer membrane and inner
membrane fractions, with the majority of MOMP was in the outer membrane fraction. The
results from the controls suggested that the inner membrane fraction contained some outer
membrane proteins, while the outer membrane fraction was pure. Based on the blotting
results and in reference to the controls, it was concluded that Cj0089 is associated with the
inner membrane, while Cj0091 is associated with outer membrane of C. jejuni.
Cj0089 and Cj0091 were inactivated in the insertional mutants. To study the
functions of the lipoproteins, insertional mutations of cj0089 and cj0091 were generated as
described in Materials and methods (Fig. 5A). Correct insertion and orientation of the KanR
cassette in Cj89- and Cj91- were confirmed by PCR (Fig. 5B). The disruptions of cj0089 and
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cj0091 were also confirmed by immunoblotting using anti-Cj0089 and anti-Cj0091 (Fig. 5C).
In Cj89-, the expression level of cj0091 was significantly decreased, but was not abolished
(Fig. 5C), indicating that the insertion in cj0089 caused a partial polar effect on cj0091.
Cj0091 is required for Campylobacter adherence to INT 407 cells in vitro. Some
proteins associated with cell membranes in C. jejuni, such as JlpA (29), CapA (5), PEB1a
(49), CadF (32) and MOMP (43), play roles in adhesion to human cells in vitro. Since
Cj0091 is an outer membrane-associated protein and has a domain homologous to SpaP
involved in surface adherence, it is possible that Cj0091 is involved in the interaction
between C. jejuni and host cells. To examine this possibility, the ability of NCTC 11168 and
the two mutants, Cj89- and Cj91-, to adhere to the monolayers of human intestinal cell line
INT 407 was measured using a cell culture system (Fig. 6). Cj91- showed a 6.7-fold
reduction in adherence compared to the wild-type, a statistically significant reduction (P <
0.05). Cj89- had a 1.64-fold reduction in adherence compared to the wild type; however, the
difference was not statistically significant (p > 0.05). These findings indicate that Cj0091, but
not Cj0089, contributes significantly to Campylobacter adherence to INT 407 cells.
Cj0091 is involved in intestinal colonization in chicken. To test whether Cj0089 and
Cj0091 has a role in chicken colonization, the wild type, Cj89-, and Cj91- were separately
inoculated to three groups of chickens. At DPI 3, 6, and 9, cecal contents were collected from
5 chickens from each group and cultured for enumeration of Campylobacter using selective
plate counting. On DPI 3 and 6, the mean level of colonization by Cj91- was significantly
lower (reduced approximately 2.7 and 2.5 log10 units, respectively) than that of the wild type
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strain (Fig. 7A). The differences were statistically significant (p < 0.05). On DPI 10, no
significant differences in colonization between the wild-type and Cj91- were observed (Fig.
7A). Throughout the experiment, no differences in colonization were observed between the
wild-type and cj89- (Fig. 7A). The colonization reduction seen with Cj91- was not
attributable to the difference in in vitro growth rates or motility because the mutants grew
equally well and were equally motile when compared with the wild-type strain (Fig. 7B,
Table 4). Together, these results indicate that Cj0091, not Cj0089, contribute to the early
colonization of C. jejuni in the intestinal tract of chickens.
Cj0091 is expressed and immunogenic in chickens. The contribution of Cj0091 to
adherence and in vivo colonization prompted us to determine if Cj0091 is produced and
immunogenic in chickens naturally infected by Campylobacter. For this purpose, rCj0091
was used as the antigen on a immunoblot and was probed with chicken sera collected from 5
individual chickens, among which 4 contained natural maternal antibodies against C. jejuni
and the other one was a negative control (Campylobacter-free and no anti-Campylobacter
maternal antibodies) (59). As shown in Fig. 8, the 21-kDa rCj0091 was detected by the 4
sera, in which high level of C. jejuni-specific maternal antibodies (IgG) were present, but not
by the serum in which the C. jejuni-specific maternal antibodies were absent (59) (Fig 8).
These findings strongly suggest that Cj0091 was produced and immunogenic during the
infection of chickens by C. jejuni.
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Discussion
In this study, we characterized an operon encoding three lipoproteins, Cj0089, Cj0090,
and Cj0091. It was found that this operon is regulated by CmeR, possibly by an indirect
mechanism. We also demonstrated that Cj0091, but not Cj0089, has an important role in
mediating Campylobacter adherence to INT 407 cells and in Campylobacter colonization of
the gastrointestinal tract of chickens, especially in the early stage of the infection. These
findings identify a new adhesin in C. jejuni and provide new insights into the pathogenic
mechanism of C. jejuni.
BLAST searches showed that Cj0089 is similar to the tetratricopeptide TPR-2 repeat
protein of Shewanella spp. (E-value = 4e-19 to 4e-16). The tetratricopeptide repeat (TPR) is a
structural motif, which mediates protein-protein interactions. TPR-containing proteins have
diverse functions. They are, for example, involved in the regulation of cell cycles, protein
transport, the regulation of transcription, splicing events, and protein folding (10, 24).
Proteins containing the TPR motif have been found in various organisms including bacteria,
yeast, plants, insects, and animals (10, 24). At present the function of Cj0089 is unknown.
Since cj0089, cj0090, and cj0091 form an operon, it is possible that the three encoded
products have a functional link. This possibility remains to be defined in future studies.
Cj0091 has a conserved domain homologous to the collagen-binding surface adhesin, SpaP
(antigen I/II family) of Yersinia pestis biovar Orientalis. spaP was first identified in
Streptococcus mutans as a gene encoding antigen I/II (55, 70), and is also known as P1 (21),
PAc (45, 46, 61), Antigen B (54, 58), IF (26), and MSL-1 (18). The antigen P1, encoded by
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spaP, plays a role in adherence of Streptococcus mutans to the salivary pellicle of tooth
surfaces or to other microorganisms (19, 23, 35, 39).
In this study we confirmed the regulation of the putative lipoprotein operon by CmeR
(Fig. 2). Based on the result of electrophoretic gel mobility shift assay, it appears that this
operon is indirectly regulated by CmeR (Fig. 3). However, we cannot exclude the possibility
that the binding region of CmeR is further upstream of the promoter of cj0089 and was not
included in the DNA fragment used for the gel-mobility shift assay. Analysis of the upstream
sequence did not identify the typical inverted repeat found in the promoter region of cmeABC
recognized by CmeR (36). Since CmeR is expected to serve as an activator for the
lipoprotein operon, which is in contrast to the regulation of cmeABC (repressed by CmeR),
the binding site for CmeR in front of the lipoprotein operon could be different from the one
in front of cmeABC. It is also possible that CmeR requires a co-factor for binding.
Alternatively, CmeR may regulate another regulatory protein, which then directly modulates
the transcription of the lipoprotein operon. How CmeR regulates the liproprotein operon and
the biological consequences of the regulation remain to be examined in future studies.
The contribution of Cj0091 to Campylobacter adherence was identified using the human
intestinal epithelial cell line INT 407 (Fig. 6). So far adhesins characterized in C. jejuni
include PEB1 (49), CadF (32), MOMP (43), JlpA (29), and CapA (5). All of these are
membrane associated-proteins. PEB1 is a periplasmic protein, homologous to the periplasmic
solute-binding protein component of amino acid ABC transporters (48). An important
function of PEB1 is that it binds to aspartate and glutamate, which are important sources of
58
carbon and energy for Campylobacter (48, 63). CadF, which is a surface protein, is involved
in the binding of C. jejuni to fibronectin in the host gastrointestinal epithelium and
stimulation of the host cell signal transduction pathway (32, 41). MOMP, a trimeric outer
membrane protein (11, 28), is involved in pore-forming activity (16), and assists outer
membrane structural organization and stabilization (4). Although one study suggested
MOMP could be involved in adherence (43), the exact role of MOMP in the interaction
between Campylobacter and host cells is unknown. JlpA is a lipoprotein and is involved in
interaction with host cells in vitro (29). Besides functioning as an adhesin, JlpA interacts with
surface-exposed heat shock protein 90 (Hsp90) on host cells, triggering signaling
pathways and leading to the activation of NF-B and p38 MAP kinase (30). CapA, which is
an autotransporter, is involved in the colonization of the chicken gut and plays a role in
adherence to human epithelial cells (5). Thus, C. jejuni appears to possess multiple adhesins
and the partial reduction of adherence seen with Cj91- may be explained by the
complementary effects of other adhesins.
Although we showed that Cj0091 is an outer membrane associated protein (Fig. 4), it has
yet to be determined whether this protein is located on the outer surface or is facing the
periplasmic side. Therefore, it is uncertain whether involvement of Cj0091 in the adherence
to human epithelial cells is direct or indirect. If it is located on the surface of the cells, it is
likely that Cj0091 directly interacts with human cells. If the Cj0091 is located on the
periplasmic side, it may act as a structural protein, which supports other protein(s) involved
in the direct adherence to epithelial cells. Further localization of Cj0091 is required to
confirm that the phenotypic difference observed is indeed due to the direct effect of Cj0091.
59
C. jejuni mainly colonizes in cecal and cloacal crypts (1, 9, 40). Unlike the colonization
in mammals, such as mice, swine, rabbits, monkeys, and humans, where the organism
commonly invades the host intestinal epithelial cells, C. jejuni does not usually invade the
intestinal epithelium of chickens (7, 13, 56, 57). Thus, surface colonization is an important
feature of Campylobacter infection in chickens. The differences in colonization between the
wild-type and Cj91- were only seen at the early stage (Fig. 7A). We speculate that this may
reflect the possibility that Cj0091 is only required for the initial adherence, or adaptation of
the Cj91- mutant occurs in the intestinal tract, overcoming the early defect in colonization.
Although it has been reported that Campylobacter does not directly interact with intestinal
epithelial cells but rather resides in the mucus layer of the crypts moving freely and rapidly in
chickens (9, 40), it is highly possible that adherence to gastrointestinal mucosal cell surface is
still required for successful colonization in chickens (5, 25). Indeed, independent studies
have shown that CapA and CadF are each required for Campylobacter colonization in
chickens (5, 71). In addition, another adhesion, PEB1, is also required for the optimal
colonization of Campylobacter in mice (49).
Ceca of chickens are blind-ended sacs filled with small food particles, fluid, and
microorganisms. Cecal contents are constantly moving in ceca and evacuated periodically
(15). Reduction of adherence to intestinal cells may cause difficulty in the initial
multiplication in ceca since most of the organisms will be excreted from ceca before the
successful proliferation. However, once C. jejuni is able to start multiplying successfully in
ceca, it will eventually overcome the initial impairment in colonization. This may be another
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reason why Cj91- was deficient only in the initial colonization in chickens. When mutants of
PEB1, CapA, and CadF were used for colonization studies, all showed a colonization defect
throughout the entire study periods (5, 49, 71), which is in contrast to our results. The reason
for the observed difference between Cj0091 and other reported adhesins in the level of
colonization reduction is unknown.
It was demonstrated in this study that Cj0089 is an inner membrane protein (Fig. 4).
Disruption of cj0089 did not result in significant changes in adherence and in vivo
colonization (Fig. 6, 7A). This suggests that Cj0089 is not essential for Campylobacter
growth in the intestinal tract. Alternatively, it may suggest that Cj0089 may share a
redundant function(s) with other genes in C. jejuni. Although cj0089 and cj0091 are located
in the same operon and both are regulated by CmeR, they may have different functions in
Campylobacter. Interestingly, mutation of cj0089 reduced, but did not abolish, the expression
of cj0091 due to a polar effect (Fig. 5c). The partial reduction in Cj0091 expression did not
cause an apparent phenotypic change, suggesting that partial production of Cj0091 is
sufficient for adherence and colonization at the wild-type level.
Another interesting finding in this study is that Cj0091 is abundant in C. jejuni in vitro
and is apparently immunogenic in chickens. To date, no vaccines against Campylobacter are
available for humans or poultry. The fact that the Campylobacter is commensal in poultry
and that it shows high genetic and antigenic diversity among different strains makes the
development of an effective vaccine quite difficult. One of the promising vaccine candidates
is an attenuated Salmonella strain carrying the C. jejuni CjaA antigen (67). CjaA is a highly
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immunogenic protein that is well conserved among different Campylobacter serotypes and
induces protective immune responses in chickens (67). Cj0091 is also highly conserved
among the 4 sequenced strains of C. jejuni ( 99 % amino acid identity). This fact plus the
findings from this study suggest that Cj0091 may be used as potential vaccine candidate in
the control of C. jejuni colonization in chickens. This possibility will be examined in future
studies.
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TABLE 1. Representative genes regulated by CmeR
*Mean of three independent experiments.
-1.9-2.60.0087Probable periplasmic proteinCj0092
-4.5-4.30.0200Putative lipoproteincj0091
-2.0-2.10.0419Putative lipoproteincj0089
6.87.80.0017cmeB, RND-type transportercj0366c
Fold change
by real-time
RT-PCR*
Fold change
by
microarray
P-valueDescriptionGene ID
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TABLE 2. Bacterial strains and plasmids used in this study
Plasmid or strain Relevant characteristics Source or reference
Strains
C. jejuni
NCTC 11168 originally isolated from human (47)
Cj89- 11168 derivative; cj0089::Kanr This study
Cj91- 11168 derivative; cj0091::Kanr This study
E. coli
DH5
F-80lacZM15 (lacZYA-argF)U169 recA1 endA1-
hsdR17 (rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 - Invitrogen
JM109
endA1 recA1 gyrA96 thi hsdR17 (rk-, mk+) relA1-
supE44 (lac-proAB)[F' traD36 proAB lacIqZM15] Promega
Plasmids
pUC19 E. coli cloning vector (69)
pUC19-89 pUC19 containing full-length cj0089, Ampr This study
pUC19-89K pUC19-89 derivative carrying cj0089::Kanr This study
pUC19-91 pUC19 containing full-length cj0091, Ampr This study
pUC19-91K pUC19-89 derivative carrying cj0091::Kanr This study
pMW10 E. coli - C. jejuni shuttle vector with a promoterless lacZ gene, Kanr (66)
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TABLE 3. Primer sequences used in this study
Primer Sequence*
cj0089-F5 5'-GAGgcatgcCCGACTTTGTTAGGTGCAGTGCAA-3' (Sph I)
cj0089-R5 5'-GCAgagctcGCTGGAATTCTAAGGGCTTGATAGTCCT-3' (Sac I)
cj89-U2 5'-GCTccatggTGCCTTATCTTGACGCATTAAAACACG-3' (Nco I)
cj89-L2 5'-CAGccatggGGGAAGCTTCTTTTGCAAATTTAAATATAAATGG-3' (Nco I)
cj0091-F2 5'-GTGCGTtctagaAGAGGTTTACCAAAAAGTA-3' (Xba I)
cj0091-R2 5'-CTTTTGGgagctcATCAAATTCCTTAGCATTCGTA-3' (Sac I)
cj0089F 5'-AGTggatccTGCCTTTTTTTAACAGCTTGTG-3' (BamH I)
cj0089R 5'-GAGgagctcTTATTTTTCCATGATAGCAAC-3' (Sac I)
cj0091-F1 5'-AGTggatccTGTGCGCAAACAGCTTATACAGATGGAAAG-3' (BamH I)
cj0091-R1 5'-GAGgagctcTTACCAAGTAACTGATTTACTAGAACCGGTTTTATC-3'(Sac I)
Pcj89-F1 5'-AGGCTTTGTATTAGCTCCTATGCTTAT-3'
Pcj89-R1 5'-CAAGCAATACCTGAAAAAATCAACCCAA-3'
cj89int-F 5'-TTTAAAATAAATATGCCTGCAATGA-3'
cj91int-R 5'-GCGATACCAATGTCCCTTTTT-3'
KanNco-F 5'-CTTATCAATATATccatggAATGGGCAAAGCAT-3'(Nco I)
KanNco-R 5'-GATAGAAccatggATAATGCTAAGACAATCACTAAA-3'(Nco I)
*The restriction sites in the sequences are indicated by lower cases. The corresponding
restriction enzymes for the restriction sites were indicated in parenthesis.
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TABLE 4. Motility of various C. jejuni constructs
7.03 ± 0.12Cj91-
6.93 ± 0.31Cj89-
7.00 ± 0.20NCTC 11168
Motility (cm)*Strain
*Mean of three independent experiments
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FIG. 1. Genomic organization and co-transcription of cj0089, cj0090, and cj0091. (A) The
genes are depicted by boxed arrows. The locations of the primers used for RT-PCR were
indicated by arrows. Predicted stem-loop encoded regions are shown by vertical oval arrows.
(B) RT-PCR was performed to determine the co-transcription of cj0089, cj0090, and cj0091
using primers cj89int-F and cj91int-R. Lane 1, no RT control; lane 2, RNA with RT and
DNA polymerase; lane 3, positive control (DNA was used as the template).
cj91int-R cj89int-F 
dcuA cj0089 cj0090 cj0091 cj0092
1 2 3
2000
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FIG. 2. Effect of cmeR mutation on the expression of Cj0089 and Cj0091 as determined by
immunoblotting. NCTC 11168 (lane 1) and cmeR (lane 2) were separated by SDS-PAGE and
probed with anti-Cj0089 (panel I), anti-Cj0091 (panel II), and anti-MOMP (panel III).
MOMP, a 45-kDa outer membrane protein, was used as to normalize the loading condition.
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Cj0089
Cj0091
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FIG. 3. Regulation of cj0089, cj0090, and cj0091, by CmeR. (A) Sequence features of the
cj0089 promoter region. Coding sequences are highlighted with gray and in bold. The
primers used to amplify DNA used for the gel shift assay are indicated by arrows. The stop
codon and terminator of dcuA, the -10 element, ribosomal binding site (RBS), and start
codon of cj0089 are underlined. (B) Gel mobility shift assay with the positive control DNA,
which contains CmeR binding site (lanes 1 and 2), negative control DNA, which is an
internal cmeA fragment (lanes 3 to 5), or cj0089 promoter DNA (lanes 6 to 8). In the assay,
the DIG-labeled DNA (0.1 pmol) was incubated with 0 (lanes 1, 3, and 6), 75 (lanes 2, 4, and
7), and 150 ng (lanes 5 and 8) of rCmeR, respectively. The position of the DIG-labeled DNA
(D) and DNA-rCmeR complex (D/P) are indicated.
1 2 3 4 5 6 7 8
D/P
D
D
(control)
GCTATTGCAATTGCTGTAGCATTAGGCTTTGTATTAGCTCCTATGCTTAT
TTAAATCAAACCCTAGGTTTTTCTCTCCTAGGGTTAAAATTTTTTCATTA
GTTTTTAAGTATATACTACGCTATAATATTCATTTTTAATTTTCTTTAAG
AAAGGAATTTAATGAAGATAAAAGTTGGGTTGATTTTTTCAGGTATTGCT
TGCCTTTTTTTAACAGCTTGTGTTAATCAGGTTAAACAAAATACAACATT
TGAAAATACTTTA
Pcj89-F1
dcuA
Pcj89-R1
cj0089
terminatorstop
startRBS
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FIG. 4. Localization of Cj0089 and Cj0091 in C. jejuni. The cytosol fraction (lane 1),
periplasm fraction (lane 2), inner membrane fraction (lane 3), and outer membrane
fraction (lane 4) were separated by SDS-PAGE and probed with anti-CmeB (panel I),
anti-Cj0089 (panel II), anti-MOMP (panel III), and anti-Cj0091 (panel IV), respectively.
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FIG. 5. Generation of deletional and insertional mutations in cj0089 and cj0091. (A)
Schematic diagram of the locations of deletional and insertional mutations. The genes are
indicated by boxed arrows. The locations of the KanR insertion are indicated as solid arrows.
(B) PCR confirmation of the insertions in Cj89- and Cj91-. Lanes 1, cj0089 in wild-type; lane
2, cj0089 in Cj89-; lane 3, cj0091 in wild-type; lane 4, cj0091 in Cj91-. (C) Immunoblotting
analysis of protein production in various constructs. Wild-type (lane 1), Cj89- (lane 2), and
Cj91- (lane 3) were separated by SDS-PAGE and probed with anti-Cj0089 (panel I), anti-
Cj0091 (panel II), and anti-MOMP (panel III). MOMP, a 45-kDa outer membrane protein,
was used as a loading control.
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FIG. 6. Adherence of C. jejuni strain NCTC 11168 and its mutants to INT 407 cells. C.
jejuni strain NCTC 11168, Cj89-, and Cj91- were inoculated onto monolayers of INT 407
cells and incubated for 3 h follwed by washing. Monolayers were lysed with 1 % Triton
X-100 in PBS and the Campylobacter cells were enumerated by plate counts.
Experiments were conducted in quadruplicate for 3 times. Adherence efficiency was
determined using the percentage of bacterial inocula adhered to cells. * P < 0.05
83
(A)
(B)
Growth curve of NCTC11168 and mutants
0
0.5
1
1.5
0 12 24 48 72
Hour
O
D
60
11168 cj89- cj91-
FIG. 7. Colonization of C. jejuni strain NCTC 11168 and its mutants in chickens.
(a) Approximately 107 CFU of each of NCTC 11168, Cj89-, or Cj91- were separately
inoculated into three groups of 3-day-old chickens. Cecal samples were collected at 3, 6, and
10 days post inoculation and the numbers of Campylobacter were enumerated by plate
counts. * P < 0.05 (b) Growth rates of NCTC 11168 and the mutants were determined by
measuring OD600 of bacterial cultures grown in MH broth.
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FIG. 8. Immunoblotting detection of natural anti-Cj0091 antibodies in chickens. Strips of
nitrocellulose membranes with rCj0091 were reacted with 4 chicken sera ( lanes 2-5) that
contained Campylobacter-specific maternal antibodies derived from natural infections
and one chicken serum (lane 6) that was negative for anti-Campylobacter antibodies.
Rabbit anti-rCj0091 was applied as a positive control (lane 1).
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CHAPTER 3. General Conclusion
In this study, we identified a three-gene operon consisting of cj0089, cj0090, and cj0091,
which encode lipoproteins. We showed that this operon is indirectly regulated by CmeR,
which functions as a repressor for the multidrug efflux pump, CmeABC. CmeR appears to
act as an activator for the lipoprotein-encoding operon because the expression of the
lipoproteins was reduced in the cmeR mutant. The findings in this study further confirm the
results of our DNA microarrays that CmeR is a pleiotropic regulator and modulates the
expression of multiple genes of diverse functions in C. jejuni. Analysis of cellular fractions
determined that Cj0089 is located on the inner membrane, while Cj0091 is associated with
the outer membrane of Campylobacter cells. At present, it is unknown if Cj0091 faces
outward or inward on the outer membrane and the specific location of Cj0091 remains to be
determined in future studies. Notably, our work revealed that Cj0091 plays a significant role
in C. jejuni adhesion to host cells in vitro and also contributes to the colonization of C. jejuni
in the gastrointestinal tracts of chickens. In addition, our results strongly suggested that
Cj0091 was produced and immunogenic in chickens that were naturally infected by C. jejuni.
Although cj0089 and cj0090 are co-transcribed with cj0091, a definitive function of Cj0089
was not identified and the characterization of Cj0090 was not performed in this work.
Findings from this study established Cj0091 as a newly identified adhesin in C. jejuni
and improved our understanding of the pathogenic mechanisms of this enteric pathogen.
Cj0091 appears to be highly conserved in different strains of C. jejuni and plays an important
role in the interaction between C. jejuni and host cells. In addition, C. jejuni is highly
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immunogenic in the animal host. These features of Cj0091 make it a promising candidate for
the development of vaccines against C. jejuni, which will be pursued in future studies.
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